Skip to main content

Table 5 Association between SNPs in IL-27 and patient’s survival

From: Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer

SNP/genotype

 

NMIBC

 

MIBC

 

Alive/dead, N

HR (95 % CI)a

P

Recurrence/Non-recurrence

HR (95 % CI)a

P

Alive/dead, N

HR (95 % CI)a

P

Recurrence/Non-recurrence

HR (95 % CI)a

P

rs153109

            

 AA

60/6

  

44/22

  

41/20

  

39/22

  

 AG

82/5

  

64/23

  

58/15

  

55/18

  

 GG

21/2

  

18/5

  

19/3

  

15/7

  

 Dominant

 

1.58 (0.53–4.72)

0.41

 

1.49 (0.85–2.60)

0.17

 

1.76 (0.93–3.33)

0.09

 

1.25 (0.70–2.23)

0.46

 Recessive

 

1.02 (0.22–4.69)

0.98

 

0.68 (0.27–1.74)

0.42

 

0.42 (0.13–1.38)

0.15

 

0.91 (0.40–2.07)

0.82

 Overdominant

 

0.63 (0.21–1.94)

0.42

 

0.80 (0.46–1.41)

0.44

 

0.81 (0.42–1.56)

0.53

 

0.84 (0.46–1.53)

0.56

rs17855750

            

 TT

137/12

  

105/44

  

90/36

  

87/39

  

 TG

25/1

  

20/6

  

26/1

  

20/7

  

 GG

1/0

  

1/0

  

2/1

  

2/1

  

 Dominant

 

0.39 (0.05–3.10)

0.37

 

0.59 (0.24–1.42)

0.24

 

0.21 (0.05–0.90)

0.035

 

0.81 (0.37–1.77)

0.60

 Recessive

 

0 (0-NA)

0.99

 

0 (0-NA)

0.97

 

1.09 (0.14–8.45)

0.94

 

1.40 (0.18–10.76)

0.75

 Overdominant

 

0.42 (0.05–3.35)

0.41

 

0.61 (0.25–1.49

0.28

 

0.12 (0.02–0.88)

0.037

 

0.76 (0.33–1.74)

0.52

  1. N corresponds to the number of individuals
  2. aAdjusted by age, sex and smoking status
  3. Boldfaced values indicate a significant difference at the 5 % level